Testing a lab-made red blood cell treatment for advanced cancers
Part of Blood & lymphatic, Cancer clinical trials.
This early trial studies whether an engineered (lab-made) red blood cell treatment is safe and tolerable, and whether it may show early anti-cancer activity. It may help people with advanced cancers whose disease has not responded well to standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old when you sign consent.
- You have advanced cancer that has been confirmed by biopsy or lab tests.
- Your cancer has had at least one previous treatment, and your most recent treatment was a PDx (patient-derived) blood-cell therapy plan (as defined by the study) or you cannot tolerate standard therapy.
- You have at least one measurable tumor spot that doctors can track on scans (different rules for solid tumors vs. lymphomas).
- You are well enough for treatment (ECOG 0 or 1) and expected to live at least 12 weeks.
- You did not start new whole-body (systemic) anti-cancer treatment after your most recent progression, and progression was within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new treatment that attaches an immune-boosting drug to your red blood cells. It is for people with advanced solid tumors who have not responded to standard treatments or cannot take them.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.